Table 1 Characteristics of included studies (n = 30)
Author | Year | Study design | Country | Assay | No. | No. HIV+ | ART-treated | Gender no. (%Male) | CD4 count | Log HIV-1 RNA levels (copies/ml) | Platelet counts (× 103/μL) | Quality assessment Reporting bias (10)/external validity (3)/internal validity (7)/selection bias (6) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aukrust | 1997 | CS | Norway | EIA | 73 | 53 | 41 | 75.47 | NR | 3.3 ± 2.6 | NR | 6/0/2/0 |
Baker | 2012 | RCT | USA | ELISA | 248 | 248 | 134 | 75.0 | 1055.33 ± 23.5 | 5.01 ± 4.05 | NR | 8/0/4/1 |
Bordoni | 2020 | PCO | Italy | Luminex | 50 | 43 | 43 | NR | 1351.5 ± 83 | 6.34 ± 5.51 | NR | 6/0/4/1 |
Corrales-medina | 2010 | CS | USA | FC | 55 | 28 | 28 | NR | NR | < 1.7 | NR | 8/1/3/1 |
Damien | 2013 | CS | France | ELISA | 111 | 71 | 41 | 34 (83) | 1427.5 ± 77.5a | < 1.7 | 540 ± 18.25a | 7/1/4/2 |
Davison | 2013 | CS | USA | ELISA | 35 | 23 | 23 | 434 ± 303.4 | < 2.6 | NR | 5/0/4/0 | |
Larranaga | 2006 | CS | Argentina | ELISA | 85 | 85 | 35 | 56 (66) | 967.06 | 5.33 ± 5.42 | NR | 6/0/3/0 |
De Luca | 2000 | CS | Italy | ELISA | 67 | 57 | 37 | 45.5 ± 4.75 | 5.8 ± 5 | NR | 6/0/4/1 | |
Donhauser | 2012 | PCO | Switzerland | ELISA | 130 | 114 | 62 | 48 (77.4) | 1098.5 ± 88.5 | 5.8 ± 1.3 | NR | 6/1/3/0 |
Francisci | 2009 | RCO | Italy | CBA | 84 | 56 | 56 | 43 (76.8) | 206.4 ± 196.6 | 4.96 ± 0.5a | NR | 10/2/5/3 |
Guzmán-Fulgencio | 2011 | CS | Spain | CBA | 96 | 73 | 73 | 58 (79.5) | 1576.67 ± 78.2 | UD | NR | 8/0/3/2 |
Jenabian | 2014 | CS | Canada | Luminex | 55 | 37 | 41 | 41 (74.5) | 533.17 ± 269.2 | < 1.6c | 265.64 ± 103 | 8/0/3/0 |
Kalayjian | 2009 | CC | USA | ELISA | 152 | 152 | 41 | 98 (88) | 257.1 ± 54.5 | 2.83 ± 2.25 | NR | 10/0/4/2 |
Kasang | 2012 | CS | Germany | ELISA | 40 | 30 | 10 | 33 (83) | 1225.62 ± 87.7 | 2.0 ± 1.90d | NR | 7/0/3/0 |
Kieballa | 2015 | CS | USA | FC | 98 | 37 | 37 | 29 (78) | 556 ± 248 | 2.16 ± 2.20 | NR | 7//1/3/0 |
LandrØ | 2011 | PCO | Norway | ELISA | 84 | 60 | 30 | 45 (75) | 151 ± 21 | 2.99 ± 2.4 | NR | 6/1/4/0 |
Li | 2015 | RCO | USA | Luminex | 163 | 122 | 80 | 55 (69) | 1644.4 ± 365.8 | 1.50 ± 1.71 | NR | 8/0/3/0 |
Mesquita | 2018 | CS | Brazil | FC | 66 | 30 | 30 | 14 (46.6) | 1383 ± 151a | < 1.7 | 458.75 ± 17.5 | 7/1/3/1 |
O’Brien | 2013 | PCO | USA | LTA, ELISA | 69 | 25 | 25 | 19 (76) | 1620 ± 235.7 a | < 1.7 | 501.5 ± 19.25 | 8/1/3/3 |
O’Halloran | 2015 | PCO | Ireland | ECL | 40 | 25 | 25 | 15 (60) | 827 ± 49.5 a | 4.39 ± 0.13a | 662 ± 20 | 8/1/4/2 |
Pastori | 2015 | CS | Italy | ELISA | 70 | 50 | 36 | 25 (69.4) | 786.9 ± 354.6 | < 1.7 | 191.8 ± 12.9 | 8/3/3/3 |
Quiros-Roldan | 2020 | RCO | Italy | ELISA | 36 | 36 | 36 | 30 (83.3) | 429.5 ± 249.2 | 4.39 ± 4.51 | NR | 8/0/4/2 |
Rōnsholt | 2013 | CS | Denmark | Luminex | 86 | 70 | 70 | 64 (91) | 630 | < 1.4b | 531.9 ± 34.40 | 7/1/4/3 |
Satchell | 2010 | CC | Ireland | LTA | 20 | 20 | 16 | 13 (65) | 773.5 ± 69.25a | 3.44 ± | 536.5 ± 26.75 | 7/1/3/0 |
Singh | 2014 | CC | USA | FC | 17 | 8 | 8 | NR | NR | NR | NR | 7/0/3/0 |
Sipas | 2002 | CS | Greece | ELISA | 94 | 77 | 77 | 67 (85) | 335 ± 248 | 5.03 ± 4.2 | NR | 6/0/3/0 |
Tunguputri | 2014 | CS | The Netherlands | FC | 110 | 80 | 80 | 64 (80) | 683.5 ± 248.6 | ≤ 1.6 | 215.8 ± 44 | 7/1/4/2 |
von Hentig | 2008 | CC | Germany | FC | 18 | 18 | 18 | 16 (88) | 145 ± 112 | 5.08 ± 0.64 | NR | 7/1/3/2 |
Wolf | 2012 | Cohort | Switzerland | ELISA | 61 | 40 | 40 | 39 (97.5) | 764 ± 155.2 a | 2.3 ± 1.95 | 202 ± 89 | 8/2/4/3 |
Wooten | 2013 | RCT | USA | ELISA | 129 | 107 | 107 | 98 (91.6) | 504.3 ± 302.05 | 2.31 ± 3.70 | NR | 6/0/3/1 |